Cargando…
The Remarkable Selectivity of Nirmatrelvir
[Image: see text] The SARS-CoV-2 main protease is among the most attractive targets for the development of therapeutic interventions for COVID-19. Successful candidate agents will not only possess potent on-target activity versus SARS-CoV-2 M(pro) but also minimal polypharmacology versus human cyste...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical Society
2022
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128007/ https://www.ncbi.nlm.nih.gov/pubmed/35702394 http://dx.doi.org/10.1021/acsptsci.2c00065 |
| _version_ | 1784712472403378176 |
|---|---|
| author | Duveau, Damien Y. Thomas, Craig J. |
| author_facet | Duveau, Damien Y. Thomas, Craig J. |
| author_sort | Duveau, Damien Y. |
| collection | PubMed |
| description | [Image: see text] The SARS-CoV-2 main protease is among the most attractive targets for the development of therapeutic interventions for COVID-19. Successful candidate agents will not only possess potent on-target activity versus SARS-CoV-2 M(pro) but also minimal polypharmacology versus human cysteine proteases. This Viewpoint explores the activity profile of the first approved SARS-CoV-2 M(pro) inhibitor (Nirmatrelvir) versus a panel of cysteine proteases and considers the therapeutic implications of the data. |
| format | Online Article Text |
| id | pubmed-9128007 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Chemical Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91280072022-05-25 The Remarkable Selectivity of Nirmatrelvir Duveau, Damien Y. Thomas, Craig J. ACS Pharmacol Transl Sci [Image: see text] The SARS-CoV-2 main protease is among the most attractive targets for the development of therapeutic interventions for COVID-19. Successful candidate agents will not only possess potent on-target activity versus SARS-CoV-2 M(pro) but also minimal polypharmacology versus human cysteine proteases. This Viewpoint explores the activity profile of the first approved SARS-CoV-2 M(pro) inhibitor (Nirmatrelvir) versus a panel of cysteine proteases and considers the therapeutic implications of the data. American Chemical Society 2022-05-17 /pmc/articles/PMC9128007/ /pubmed/35702394 http://dx.doi.org/10.1021/acsptsci.2c00065 Text en Not subject to U.S. Copyright. Published 2022 by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Duveau, Damien Y. Thomas, Craig J. The Remarkable Selectivity of Nirmatrelvir |
| title | The Remarkable Selectivity of Nirmatrelvir |
| title_full | The Remarkable Selectivity of Nirmatrelvir |
| title_fullStr | The Remarkable Selectivity of Nirmatrelvir |
| title_full_unstemmed | The Remarkable Selectivity of Nirmatrelvir |
| title_short | The Remarkable Selectivity of Nirmatrelvir |
| title_sort | remarkable selectivity of nirmatrelvir |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128007/ https://www.ncbi.nlm.nih.gov/pubmed/35702394 http://dx.doi.org/10.1021/acsptsci.2c00065 |
| work_keys_str_mv | AT duveaudamieny theremarkableselectivityofnirmatrelvir AT thomascraigj theremarkableselectivityofnirmatrelvir AT duveaudamieny remarkableselectivityofnirmatrelvir AT thomascraigj remarkableselectivityofnirmatrelvir |